Skip to main content
Top
Published in: Journal of Bone and Mineral Metabolism 2/2016

01-03-2016 | Original Article

Phosphate enhances Fgf23 expression through reactive oxygen species in UMR-106 cells

Authors: Michiko Hori, Yuka Kinoshita, Manabu Taguchi, Seiji Fukumoto

Published in: Journal of Bone and Mineral Metabolism | Issue 2/2016

Login to get access

Abstract

Fibroblast growth factor 23 (FGF23) has been shown to work as a phosphotropic hormone. Although FGF23 reduces the serum phosphate level, it has not been established that phosphate directly regulates FGF23 production. In this study, we investigated whether phosphate can enhance Fgf23 expression using the rat osteoblastic cell line UMR-106, which has been shown to express Fgf23 in response to 1,25-dihydroxyvitamin D [1,25(OH)2D]. Phosphate increased Fgf23 expression in a dose- and time-dependent manner in the presence of 1,25(OH)2D. Phosphate also increased Fgf23 promoter activity, but showed no effect on the half-life of Fgf23 messenger RNA. Phosphonoformic acid and PD98059, an inhibitor of MEK, inhibited the effects of phosphate on Fgf23 expression and promoter activity. In addition, phosphate enhanced production of reactive oxygen species (ROS) in UMR-106 cells, and hydrogen peroxide enhanced FGF23 production in a dose- and time-dependent manner. Hydrogen peroxide also enhanced Elk1 reporter activity, a target of the MEK–extracellular-signal-regulated kinase (ERK) pathway. Furthermore, the effect of phosphate on ROS production and Fgf23 expression was inhibited by apocynin, an inhibitor of NADPH oxidase. These results indicate that phosphate directly enhances Fgf23 transcription without affecting the stability of Fgf23 messenger RNA by stimulating NADPH-induced ROS production and the MEK–ERK pathway in UMR-106 cells.
Literature
1.
go back to reference Shimada T, Hasegawa H, Yamazaki Y, Muto T, Hino R, Takeuchi Y, Fujita T, Nakahara K, Fukumoto S, Yamashita T (2004) FGF-23 is a potent regulator of vitamin D metabolism and phosphate homeostasis. J Bone Miner Res 19:429–435CrossRefPubMed Shimada T, Hasegawa H, Yamazaki Y, Muto T, Hino R, Takeuchi Y, Fujita T, Nakahara K, Fukumoto S, Yamashita T (2004) FGF-23 is a potent regulator of vitamin D metabolism and phosphate homeostasis. J Bone Miner Res 19:429–435CrossRefPubMed
2.
3.
go back to reference Carpenter TO (2012) The expanding family of hypophosphatemic syndromes. J Bone Miner Metab 30:1–9CrossRefPubMed Carpenter TO (2012) The expanding family of hypophosphatemic syndromes. J Bone Miner Metab 30:1–9CrossRefPubMed
4.
go back to reference Ferrari SL, Bonjour JP, Rizzoli R (2005) Fibroblast growth factor-23 relationship to dietary phosphate and renal phosphate handling in healthy young men. J Clin Endocrinol Metab 90:1519–1524CrossRefPubMed Ferrari SL, Bonjour JP, Rizzoli R (2005) Fibroblast growth factor-23 relationship to dietary phosphate and renal phosphate handling in healthy young men. J Clin Endocrinol Metab 90:1519–1524CrossRefPubMed
5.
go back to reference Saito H, Maeda A, Ohtomo S, Hirata M, Kusano K, Kato S, Ogata E, Segawa H, Miyamoto K, Fukushima N (2005) Circulating FGF-23 is regulated by 1α,25-dihydroxyvitamin D3 and phosphorus in vivo. J Biol Chem 280:2543–2549CrossRefPubMed Saito H, Maeda A, Ohtomo S, Hirata M, Kusano K, Kato S, Ogata E, Segawa H, Miyamoto K, Fukushima N (2005) Circulating FGF-23 is regulated by 1α,25-dihydroxyvitamin D3 and phosphorus in vivo. J Biol Chem 280:2543–2549CrossRefPubMed
6.
go back to reference Ito N, Fukumoto S, Takeuchi Y, Takeda S, Suzuki H, Yamashita T, Fujita T (2007) Effect of acute changes of serum phosphate on fibroblast growth factor (FGF)23 levels in humans. J Bone Miner Metab 25:419–422CrossRefPubMed Ito N, Fukumoto S, Takeuchi Y, Takeda S, Suzuki H, Yamashita T, Fujita T (2007) Effect of acute changes of serum phosphate on fibroblast growth factor (FGF)23 levels in humans. J Bone Miner Metab 25:419–422CrossRefPubMed
7.
go back to reference Fukumoto S, Shimizu Y (2011) Fibroblast growth factor 23 as a phosphotropic hormone and beyond. J Bone Miner Metab 29:507–514CrossRefPubMed Fukumoto S, Shimizu Y (2011) Fibroblast growth factor 23 as a phosphotropic hormone and beyond. J Bone Miner Metab 29:507–514CrossRefPubMed
8.
go back to reference Liu S, Tang W, Zhou J, Stubbs JR, Luo Q, Pi M, Quarles LD (2006) Fibroblast growth factor 23 is a counter-regulatory phosphaturic hormone for vitamin D. J Am Soc Nephrol 17:1305–1315CrossRefPubMed Liu S, Tang W, Zhou J, Stubbs JR, Luo Q, Pi M, Quarles LD (2006) Fibroblast growth factor 23 is a counter-regulatory phosphaturic hormone for vitamin D. J Am Soc Nephrol 17:1305–1315CrossRefPubMed
9.
go back to reference Kolek OI, Hines ER, Jones MD, LeSueur LK, Lipko MA, Kiela PR, Collins JF, Haussler MR, Ghishan FK (2005) 1α,25-Dihydroxyvitamin D3 upregulates FGF23 gene expression in bone: the final link in a renal-gastrointestinal-skeletal axis that controls phosphate transport. Am J Physiol Gastrointest Liver Physiol 289:G1036–G1042CrossRefPubMed Kolek OI, Hines ER, Jones MD, LeSueur LK, Lipko MA, Kiela PR, Collins JF, Haussler MR, Ghishan FK (2005) 1α,25-Dihydroxyvitamin D3 upregulates FGF23 gene expression in bone: the final link in a renal-gastrointestinal-skeletal axis that controls phosphate transport. Am J Physiol Gastrointest Liver Physiol 289:G1036–G1042CrossRefPubMed
10.
go back to reference Shigematsu T, Kazama JJ, Yamashita T, Fukumoto S, Hosoya T, Gejyo F, Fukagawa M (2004) Possible involvement of circulating fibroblast growth factor 23 in the development of secondary hyperparathyroidism associated with renal insufficiency. Am J Kidney Dis 44:250–256CrossRefPubMed Shigematsu T, Kazama JJ, Yamashita T, Fukumoto S, Hosoya T, Gejyo F, Fukagawa M (2004) Possible involvement of circulating fibroblast growth factor 23 in the development of secondary hyperparathyroidism associated with renal insufficiency. Am J Kidney Dis 44:250–256CrossRefPubMed
11.
go back to reference Lavi-Moshayoff V, Wasserman G, Meir T, Silver J, Naveh-Many T (2010) PTH increases FGF23 gene expression and mediates the high-FGF23 levels of experimental kidney failure: a bone parathyroid feedback loop. Am J Physiol Renal Physiol 299:F882–F889CrossRefPubMed Lavi-Moshayoff V, Wasserman G, Meir T, Silver J, Naveh-Many T (2010) PTH increases FGF23 gene expression and mediates the high-FGF23 levels of experimental kidney failure: a bone parathyroid feedback loop. Am J Physiol Renal Physiol 299:F882–F889CrossRefPubMed
12.
go back to reference Babu GJ, Lalli MJ, Sussman MA, Sadoshima J, Periasamy M (2000) Phosphorylation of elk-1 by MEK/ERK pathway is necessary for c-fos gene activation during cardiac myocyte hypertrophy. J Mol Cell Cardiol 32:1447–1457CrossRefPubMed Babu GJ, Lalli MJ, Sussman MA, Sadoshima J, Periasamy M (2000) Phosphorylation of elk-1 by MEK/ERK pathway is necessary for c-fos gene activation during cardiac myocyte hypertrophy. J Mol Cell Cardiol 32:1447–1457CrossRefPubMed
13.
go back to reference Li QJ, Vaingankar S, Sladek FM, Martins-Green M (2000) Novel nuclear target for thrombin: activation of the Elk1 transcription factor leads to chemokine gene expression. Blood 96:3696–3706PubMed Li QJ, Vaingankar S, Sladek FM, Martins-Green M (2000) Novel nuclear target for thrombin: activation of the Elk1 transcription factor leads to chemokine gene expression. Blood 96:3696–3706PubMed
14.
go back to reference Hirano S, Watanabe T, Kobayashi Y (2013) Effects of arsenic on modification of promyelocytic leukemia (PML): PML responds to low levels of arsenite. Toxicol Appl Pharmacol 273:590–599CrossRefPubMed Hirano S, Watanabe T, Kobayashi Y (2013) Effects of arsenic on modification of promyelocytic leukemia (PML): PML responds to low levels of arsenite. Toxicol Appl Pharmacol 273:590–599CrossRefPubMed
15.
go back to reference Kimata M, Michigami T, Tachikawa K, Okada T, Koshimizu T, Yamazaki M, Kogo M, Ozono K (2010) Signaling of extracellular inorganic phosphate up-regulates cyclin D1 expression in proliferating chondrocytes via the Na+/Pi cotransporter Pit-1 and Raf/MEK/ERK pathway. Bone 47:938–947CrossRefPubMed Kimata M, Michigami T, Tachikawa K, Okada T, Koshimizu T, Yamazaki M, Kogo M, Ozono K (2010) Signaling of extracellular inorganic phosphate up-regulates cyclin D1 expression in proliferating chondrocytes via the Na+/Pi cotransporter Pit-1 and Raf/MEK/ERK pathway. Bone 47:938–947CrossRefPubMed
16.
go back to reference Shuto E, Taketani Y, Tanaka R, Harada N, Isshiki M, Sato M, Nashiki K, Amo K, Yamamoto H, Higashi Y, Nakaya Y, Takeda E (2009) Dietary phosphorus acutely impairs endothelial function. J Am Soc Nephrol 20:1504–1512CrossRefPubMedPubMedCentral Shuto E, Taketani Y, Tanaka R, Harada N, Isshiki M, Sato M, Nashiki K, Amo K, Yamamoto H, Higashi Y, Nakaya Y, Takeda E (2009) Dietary phosphorus acutely impairs endothelial function. J Am Soc Nephrol 20:1504–1512CrossRefPubMedPubMedCentral
17.
go back to reference Lee YS, Choi EM (2011) Apocynin stimulates osteoblast differentiation and inhibits bone-resorbing mediators in MC3T3-E1 cells. Cell Immunol 270:224–229CrossRefPubMed Lee YS, Choi EM (2011) Apocynin stimulates osteoblast differentiation and inhibits bone-resorbing mediators in MC3T3-E1 cells. Cell Immunol 270:224–229CrossRefPubMed
18.
go back to reference Okamoto T, Taguchi M, Osaki T, Fukumoto S, Fujita T (2013) Phosphate enhances reactive oxygen species production and suppresses osteoblastic differentiation. J Bone Miner Metab 32:393–399CrossRefPubMed Okamoto T, Taguchi M, Osaki T, Fukumoto S, Fujita T (2013) Phosphate enhances reactive oxygen species production and suppresses osteoblastic differentiation. J Bone Miner Metab 32:393–399CrossRefPubMed
19.
go back to reference Ito N, Findlay DM, Anderson PH, Bonewald LF, Atkins GJ (2013) Extracellular phosphate modulates the effect of 1α,25-dihydroxy vitamin D3 (1,25D) on osteocyte like cells. J Steroid Biochem Mol Biol 2013:183–186CrossRef Ito N, Findlay DM, Anderson PH, Bonewald LF, Atkins GJ (2013) Extracellular phosphate modulates the effect of 1α,25-dihydroxy vitamin D3 (1,25D) on osteocyte like cells. J Steroid Biochem Mol Biol 2013:183–186CrossRef
20.
go back to reference Isakova T, Wahl P, Vargas GS, Gutierrez OM, Scialla J, Xie H, Appleby D, Nessel L, Bellovich K, Chen J, Hamm L, Gadegbeku C, Horwitz E, Townsend RR, Anderson CA, Lash JP, Hsu CY, Leonard MB, Wolf M (2011) Fibroblast growth factor 23 is elevated before parathyroid hormone and phosphate in chronic kidney disease. Kidney Int 79:1370–1378CrossRefPubMedPubMedCentral Isakova T, Wahl P, Vargas GS, Gutierrez OM, Scialla J, Xie H, Appleby D, Nessel L, Bellovich K, Chen J, Hamm L, Gadegbeku C, Horwitz E, Townsend RR, Anderson CA, Lash JP, Hsu CY, Leonard MB, Wolf M (2011) Fibroblast growth factor 23 is elevated before parathyroid hormone and phosphate in chronic kidney disease. Kidney Int 79:1370–1378CrossRefPubMedPubMedCentral
21.
go back to reference Ruiz S, Pergola PE, Zager RA, Vaziri ND (2013) Targeting the transcription factor Nrf2 to ameliorate oxidative stress and inflammation in chronic kidney disease. Kidney Int 83:1029–1041CrossRefPubMedPubMedCentral Ruiz S, Pergola PE, Zager RA, Vaziri ND (2013) Targeting the transcription factor Nrf2 to ameliorate oxidative stress and inflammation in chronic kidney disease. Kidney Int 83:1029–1041CrossRefPubMedPubMedCentral
Metadata
Title
Phosphate enhances Fgf23 expression through reactive oxygen species in UMR-106 cells
Authors
Michiko Hori
Yuka Kinoshita
Manabu Taguchi
Seiji Fukumoto
Publication date
01-03-2016
Publisher
Springer Japan
Published in
Journal of Bone and Mineral Metabolism / Issue 2/2016
Print ISSN: 0914-8779
Electronic ISSN: 1435-5604
DOI
https://doi.org/10.1007/s00774-015-0651-9

Other articles of this Issue 2/2016

Journal of Bone and Mineral Metabolism 2/2016 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine